Clinical Trial Detail

NCT ID NCT02038036
Title Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

polycythemia vera

Therapies

Peginterferon alfa-2b

Anagrelide

Hydroxyurea

Pipobroman

Ruxolitinib

Age Groups: senior adult

No variant requirements are available.